Pyrotinib in the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: A case report

RATIONALE: Pyrotinib is a novel dual pan-ErbB receptor tyrosine kinase inhibitor, approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). However, there was still limited information regarding specific effect of pyrotinib on HER2-positiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Jiali, Chen, Yuetong, Tang, Cuiju, Wei, Xiaowei, Gong, Yang, Wei, Jingsun, Gu, Dongying, Chen, Jinfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
5750
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310977/
https://www.ncbi.nlm.nih.gov/pubmed/32569228
http://dx.doi.org/10.1097/MD.0000000000020809

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310977/
https://www.ncbi.nlm.nih.gov/pubmed/32569228
http://dx.doi.org/10.1097/MD.0000000000020809

Ejemplares similares